Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Insulin isophane, also known as neutral protamine Hagedorn (NPH) insulin, is an intermediate-acting form of human insulin used to control blood sugar in people with diabetes mellitus. It works by increasing the amount of circulating insulin, thereby lowering blood glucose levels. The onset of action typically occurs within 2 to 4 hours after injection, peaks at 4 to 12 hours, and lasts for about 12 to 18 hours. Insulin isophane helps facilitate the uptake of glucose into cells for energy and storage and compensates for insufficient endogenous production or utilization in diabetic patients. It may be used alone or in combination with other insulins or oral antidiabetic agents[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on insulin isophane.